The major driving factors rising prevalence of cardiovascular diseases, significant growth of pharmaceutical and biotechnology industries, rising need for the organ transplantation and rising cell based research activities play vital role in the growth of the medical perfusion technology market. However, the challenges such as expensive organ transplant surgeries and limited numbers of donors for organ transplant surgeries are likely to impact the growth of the market in the forecast period. On the other hand, technological development from emerging nations hold a significant opportunity for the market growth in the coming years.
The medical perfusion technology market majorly consists of the players such as companies such Getinge AB, Medtronic, LivaNova PLC, Terumo Corporation, XVIVO Perfusion, OrganOx Limited, Waters Medical Systems LLC, TransMedics, Organ Recovery Systems, and Xenios AG – a Fresenius Medical Care company. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized organic strategies such as launches, expansion, and product approvals. Whereas, the inorganic strategies such as mergers & acquisitions, partnership, collaborations, were widely seen in the medical perfusion technology market.
Getinge AB and Medtronic –are Notable Market Players in Medical Perfusion Technology Market
Several in organic approaches, such as product launches, and expansion in the medical perfusion technology market, have resulted in the positive growth of the market. Likewise, inorganic strategies such as mergers & acquisitions, and collaboration have help the company to strengthen its revenue, which allows the company to hold a strong position in the market.
Below is the list of the growth strategies done by the players operating in the medical perfusion technology market:
|
Year |
News |
|
May-2019 |
Terumo Cardiovascular Group, a world pioneer in cardiovascular surgery technology, and Talis Clinical, a major supplier of healthcare software solutions, have announced the commercial availability of ACG-Perfusion and ACG-RemoteView Systems in North America. |
|
Apr-2018 |
TransMedics, Inc. Received FDA Pre-Market Approval (PMA) for its OCS Lung System for Near-Physiologic Preservation and Assessment of Lungs for Transplantation |
|
Jun-2019 |
TransMedics Announces the Second FDA PMA Approval for its OCS Lung System, Allowing Access to a Larger Pool of Donor Lungs that are Currently Seldomly Utilized for Transplantation Due to Limitations of Cold Storage |
